NVP-LCQ195
CAS No. : 902156-99-4
(Synonyms: LCQ-195; AT9311)
| Size | Price | Stock |
|---|---|---|
| 5mg | $123 | In-stock |
| 10mg | $185 | In-stock |
| 25mg | $354 | In-stock |
| 50mg | $520 | In-stock |
| 100mg | $741 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15241 |
| M.Wt: | 460.33 |
| Formula: | C17H19Cl2N5O4S |
| Purity: | >98 % |
| Solubility: | DMSO : 66.67 mg/mL (ultrasonic) |
NVP-LCQ195 (LCQ-195) is an inhibitor of CDK1/2/3/5/9. NVP-LCQ195 induces cell cycle arrest and eventual apoptotic cell death of multiple myeloma (MM) cells. NVP-LCQ195 triggers decreased amplitude of transcriptional signatures related to oncogenesis, drug resistance and stem cell renewal in MM cell lines[1].
In Vitro:NVP-LCQ195 (Compound LCQ-195) (500 nmol/L) blocks the activity of CDK1/cyclin B and CDK2/cyclin A, as well as CDK5 in MM cell lines[1].
NVP-LCQ195 (0-4 μmol/L, 48 h) results in the EC50 of equal to or less than 1 μmol/L in most MM cell lines[1].
NVP-LCQ195 (2 μmol/L, 4-48 h) increases the percentage of cells in S and G2/M phases early, followed by an increase in sub-G1 population[1].
NVP-LCQ195 (2 μmol/L, 2-24 h) decreases the amplitude of various transcriptional signatures indicative of the activity of transcription factors (e.g. myc, HIF-1α, IRF4 and NF-κB), signalling cascades (e.g. Notch, Ras, Akt and Hedgehog), the ubiquitin/proteasome and ribosomal pathways in MM cell lines[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- NVP-LCQ195
- Cat. No.:
- HY-15241
- Quantity:
Your information is safe with us.